SXTP
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.83
−3.29%Oct 6, 2026, 12:10 UTC
60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized clinical study of tafenoquine in hospitalized babesiosis patients, with primary and secondary endpoint results expected in January 2027.
Source:Oct 1, 2026, 12:03 UTC
60 Degrees Pharmaceuticals announced that interim analysis results from its clinical study of tafenoquine in severe babesiosis will be released on October 6, 2026, along with a key opinion leader investor webinar featuring Dr. Peter Krause and Dr. Edouard Vannier.
Source:Aug 14, 2026, 19:47 UTC
60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, with net product revenues increasing approximately 106% to about $208 thousand from about $101 thousand in the same quarter of 2025.
Aug 4, 2026, 00:00 UTC
60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.
Jul 8, 2026, 12:01 UTC
60 Degrees Pharmaceuticals announced an exclusive option agreement with Florida State University to develop castanospermine for tick-borne diseases.
Source:Jun 11, 2026, 12:03 UTC
60 Degrees Pharmaceuticals signed an exclusive patent license agreement with Florida State University for non-prescription use of Australian Chestnut Extract as a botanical supplement.
Source: